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FDG PET/CT and Mediastinal Nodal
Metastasis Detection in Stage T1 
Non-Small Cell Lung Cancer: Prognostic
Implications
Objective: We aimed to compare the prognoses of patients with pathologically
true negative (P-TN) N2 and PET/CT false negative (FN) results in stage T1 non-
small cell lung cancer (NSCLC).
Materials and Methods: Our institutional review board approved this retro-
spective study with a waiver of informed consent. The study included 184 patients
(124 men and 60 women; mean age, 59 years) with stage T1 NSCLC who under-
went an integrated PET/CT and surgery. After estimating the efficacy of PET/CT
for detecting N2 disease, we determined and compared disease-free survival
(DFS) rates in three groups (P-TN [n = 161], PET/CT FN [n = 12], and PET/CT
true positive [TP, n = 11]) using the Kaplan-Meier analysis and log-rank test.
Results: Pathologic N2 disease was observed in 23 (12%) patients. PET/CT
had an N2 disease detection sensitivity of 48% (11 of 23 patients), a specificity of
95% (153 of 161), and an accuracy of 89% (164 of 184). The 3-year DFS rate in
the PET/CT FN group (31%, 95% confidence interval [CI]; 13.6-48.0%) was simi-
lar to that of the TP group (16%, 95% CI; 1.7-29.5%) (p = 0.649), but both groups
had significantly shorter DFS rates than the P-TN group (77%, 95% CI; 72.0-
81.2%) (p < 0.001).
Conclusion: The PET/CT shows a high specificity, but low sensitivity for
detecting N2 disease in stage T1 NSCLC. Patients with PET/CT FN N2 disease
have survival rates similar to PET/CT TP N2 disease patients, which are both
substantially shorter than the survival rate of P-TN patients.
ositron emission tomography (PET) with 18F-fluorodeoxyglucose (FDG)
is regarded as a more sensitive test than CT in the identification of
malignant tissues due to alterations in tissue metabolism, which generally
precede anatomic changes (1). However, PET and integrated PET/CT have a low
sensitivity (approximately 50%) for mediastinal nodal staging in the T1 non-small cell
lung cancer (NSCLC) stage (2, 3). This low sensitivity is likely attributed to the inabil-
ity to detect early stage or microscopic lymph node metastases. 
Patients with mediastinal lymph node metastases identified at mediastinoscopy have
different survival rates than metastases identified at thoracotomy only. Specifically,
the thoracotomy metastasis patients have a substantially better 5-year survival rate
(24%) than mediastinal lymph node patients (survival rate, 9%) (4). 
As mentioned above, it can be presumed that patients with a false negative (FN)
FDG PET result for mediastinal nodal metastasis have early stage or microscopic
mediastinal nodal metastases that cannot be identified by PET or PET/CT. However,
we have no empirical evidence that these unidentified mediastinal nodal metastases
automatically translate to higher survival rates (as is the case for patients with N2
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Pdisease identified at the thoracotomy but not at
mediastinoscopy) compared to patients with a true positive
(TP) PET result. Thus, the purpose of our study was to
compare the prognoses of patients with pathologically true
negative (P-TN) N2 and PET/CT FN results in stage T1
NSCLC.
MATERIALS AND METHODS
Our institutional review board approved our retrospec-
tive study with a waiver of informed consent.
Patients Enrollment
From September 2003 to July 2006, we enrolled 199
patients who underwent integrated PET/CT and surgical
staging and were diagnosed with stage T1 NSCLC at CT
(retrospective review and reanalysis of all CT data
obtained during this period) or on pathologic examination.
Because bronchioloalveolar carcinomas usually do not
have nodal or extrathoracic metastases, we excluded
patients with that type of tumor (nodule of pure ground-
glass opacity). For patients with overt extra-thoracic
metastases in which a conventional staging workup was
not suggested, (clinical examination or enhanced thoracic
CT covering down to the level of middle portion of the
kidneys), a PET/CT was performed as a further pre-
treatment staging workup.
At our institution, patients with biopsy-proved N2
disease at mediastinoscopy are usually treated by using
neoadjuvant concurrent chemo-radiation therapy (weekly
taxane/platinum and 45 Gy of radiation therapy over a 5
week period) and a subsequent surgical resection. Those
identified as negative for mediastinal nodal metastases at
mediastinoscopy, and subsequently found to have positive
mediastinal nodes after surgical resection, were adminis-
tered adjuvant chemotherapy (cisplatin-based chemother-
apy, three to four cycles of platinum combined with either
taxane or vinorelbine). In node-negative patients at both a
mediastinoscopy and thoracotomy, a curative surgical
resection was performed without any adjuvant therapy.
Of these 199 patients, 10 were excluded because they
did not undergo surgical treatment. In addition, another
five patients were excluded because of death caused by an
unrelated disease (post-operative adult respiratory distress
in two, chronic empyema in the lobectomy space and its
related pneumonia and sepsis in one, advanced gastric
cancer in one, and acute pulmonary thromboembolism in
one) during the follow-up period. The remaining patients
make up the total of 184 patients included in the study
(124 men and 60 women; mean age, 59 + 10 years
[standard deviation]; range, 32-81 years) (Fig. 1).
Image Acquisition
Details of the imaging methods used have been described
in previous reports (1-3). Briefly, peripheral blood glucose
was < 150 mg/dL in all patients. Patients received an
intravenous injection of 370 MBq (10 mCi) of FDG and
then rested for over 45 minutes before scanning. Scans
were acquired using a PET/CT unit (Discovery LS; GE
Healthcare, Milwaukee, WI) consisting of a PET scanner
(Advance NXi; GE Healthcare,) and an eight-slice CT
scanner (LightSpeed Plus; GE Healthcare). A CT was
performed from the head to the pelvic floor according to a
standard protocol using the following settings: 140 kVp; 80
mA; tube rotation time, 0.5 seconds per rotation; slice
pitch, 6; and section thickness, 5 mm (to match the PET
section thickness). Each patient maintained normal shallow
respiration during the acquisition of CT and PET scans.
Immediately after an unenhanced CT, an emission PET
was performed in the identical transverse field of view.
The PET data sets were reconstructed iteratively using an
ordered subset expectation maximization algorithm and by
applying the segmented attenuation correction (two
iterations, 28 subsets) to the CT data. The co-registered
images were displayed using Xeleris software (GE
Healthcare).
Analyses of PET/CT Images
Integrated PET/CT images were evaluated jointly and
prospectively by a chest radiologist (with 18 years of CT
interpretation experience and 4 years of PET/CT interpre-
tation) and a nuclear medicine physician (with 13 years of
experience and 4 years of PET/CT analysis). Both were
unaware of the findings of clinical and pathological evalua-
tions. Primary tumor size was determined by measuring
the largest diameter of the primary tumor on transverse
lung window (window width, 1,500 HU; window level, -
700) images seen at the CT component of the PET/CT
images. The maximum standardized uptake values
(mSUVs) of primary tumors were measured by placing an
region of interest. 
Nodal stations were assessed visually by allocating
mediastinal lymph nodes to nine groups, according to the
lymph node map definition for lung cancer staging
proposed by Mountain and Dresler (5). All lymph nodes in
the thorax with abnormal FDG uptake (greater than
mediastinal blood pool uptake), irrespective of their size,
were considered metastatic. Enlarged lymph nodes with
their short-axis diameter > 10 mm were designated as
benign when they were negative at the PET component of
PET/CT images. Additionally, lymph nodes even with high
FDG uptake, when they showing higher attenuation than
mediastinal structures (great vessels) or benign calcification
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regarded as being benign (1-3).
Surgery and Pathologic Evaluation of Mediastinal
Nodes
During a mediastinoscopy, one of three surgeons (19, 14,
and 6 years of experience, respectively) attempted to
harvest entire nodes, and the American Thoracic Society
(ATS) lymph node map areas of 2R, 4R, 2L, 4L, and 7
were routinely sampled. During a thoracotomy, the
surgeons sampled all visible and palpable lymph nodes that
were accessible in the hilum and mediastinum according to
our surgical protocol. Namely, all encountered lymph
nodes were removed from the ATS lymph node map areas
10R, 9, 8, 7, 4R, 3 and 2R in tumors of the right lung, and
from map areas 10L, 9, 8, 7, 6, 5 and 4L of the left lung.
When necessary, especially when imaging results suggested
the presence of possible nodal metastasis in nodal stations
of group 1 (highest mediastinal) or 2L (when tumor was
located in the left lung) nodes, the nodes were also
evaluated during a mediastinoscopy or thoracotomy.
A lung pathologist with 13 years of experience evaluated
the nodes as numbered in the surgical field (surgeons
labeled dissected lymph nodes by numbering the nodes
according to the lymph node map definition for lung
cancer staging) (5). 
Follow-up and Assessment of Tumor Recurrence
We subdivided patients into three groups according to
PET/CT and pathologic findings for mediastinal lymph
node metastasis, i.e., the pathologically true negative (P-
TN = TN + FP at PET/CT), PET/CT FN, and PET/CT TP
groups. 
A follow-up evaluation was performed every three
months for the first two years after operation and six
months thereafter. A chest CT covering the whole thorax
and upper abdomen was routinely performed at each
follow-up study. If patients became symptomatic or
demonstrated abnormal laboratory findings, appropriate
tests (i.e., brain MR, spine MR and bone scintigraphy) were
also performed. The median follow-up time following
surgery in the 184 patients was 23 months (range, 10-44
months).
Statistical Analyses
The statistical analysis was performed using the SPSS
statistical software version 9.0 (SPSS Inc, Chicago, IL). The
characteristics of the patients in the P-TN, PET/CT FN, and
PET/CT TP groups were compared using the Fisher’s exact
test or the Chi-square test. The nonparametric data were
analyzed by using the Kruskal-Wallis test. The differences
in nodule size (< 2 cm versus > 2 cm in diameter) of
primary cancers between N2 and N0/N1 patients were
compared by using the Chi-square test.
Disease-free survival (DFS) and overall survival (OS)
times were measured from the date of surgery until the
first evidence of disease recurrence or last date of follow-
up for patients who remained alive and were free of
disease. DFS and OS were determined by using Kaplan-
Meier analysis, and the differences between groups (P-TN,
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Fig. 1. Flowchart illustrating study design
and number of patients enrolled in this
study from each group. P-TN = patholog-
ically true negative, TN = true negative,
FP = false positive, FN = false negative,
TP = true positive, *Neither FDG uptake
amount of primary tumor or PET/CT
mediastinal nodal FDG uptake result was
determinant for performing
mediastinoscopy.PET/CT FN, and PET/CT TP) groups were compared by
using the log-rank test.  
A univariate Cox regression analysis was used to
determine whether the mSUV integer values between
three and 10 were predictive of tumor recurrence. In
addition, a univariate analysis was performed to evaluate
the relationships between clinical or histologic prognostic
factors and the probability of tumor recurrence after
surgical resection. The model was adjusted for the effects
of pathologic groups (P-TN, PET/CT FN, and PET/CT true
positive), patient age and sex, cell type, tumor size, mSUV
of the tumor, and the number of nodal stations involved.
Next, a multivariate analysis was performed to identify
independent prognostic determinants (Cox proportional
hazards model) for both DFS and OS. Differences at the p
< 0.05 level were defined as being statistically significant.
RESULTS
Patients (n = 184)
A total of 184 patients (124 men and 60 women; mean
age, 59 + 10 years [standard deviation]; range, 32-81
years) were included in the study. The surgical procedures
performed included a bilobectomy in three patients, a
lobectomy in 179 patients, and a segmentectomy or wedge
resection in two patients. Histologically, 132 patients had
adenocarcinoma, 40 had squamous cell carcinoma, and 12
had other carcinomas (large cell neuroendocrine carcino-
mas in 5, large cell carcinoma in 4, sarcomatoid carcinoma
in 2, and pleomorphic carcinoma in 1).
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Fig. 2. False negative PET/CT interpre-
tation for mediastinal nodal staging in 42-
year-old woman with stage T1 adenocar-
cinoma of lung showing recurrent
disease on follow-up examination.
A, B. Transverse (A) and coronal (B)
images of initial PET/CT show 20-mm-
sized nodule (arrows) in right lower lobe
(maximum SUV = 9.5). There was no
identifiable mediastinal uptake, but
thoracotomy disclosed malignant cells in
right lower paratracheal (nodal station
4R) and subcarinal (station 7) nodes. 
C, D. 9-month follow-up transverse CT
(C) and coronal PET (D) scans
demonstrate 20-mm-sized right anterior
diaphragmatic node (arrows) with high
amount FDG uptake (maximum SUV =
7.0), which is suggestive of recurrent
disease.
AB
CDA mediastinoscopy was performed in 19 patients and its
sensitivity for detecting N2 disease was found to be 79%
(15 of 19 patients) (Fig. 1). N2 disease was observed in 23
(12%) patients. Moreover, seven of the 89 patients (8%)
with smaller tumors (< 2.0 cm in diameter) and 16 of the
95 patients (17%) with tumors > 2.0 cm had N2 nodal
metastases (p = 0.077). All 23 patients with N2 nodal
metastases had a primary tumor with mSUVs of > 5 (mean
= 9.9, (indicate unit of measure) range; 5.1-17.5 cm
(indicate unit of measure)). The remaining 161 patients
without nodal metastases had a primary tumor with a
mean mSUV of 7.06 (range; 0.4-22.5) (p = 0.003, Mann-
Whitney test).
Neoadjuvant therapy was performed in 15 patients in
whom a mediastinoscopy revealed a malignant lymph
node diagnosis. In these patients, a thoracotomy was
followed by the neoadjuvant therapy. Next, postoperative
adjuvant therapy was administered in eight patients in
whom a thoracotomy pathology revealed a malignant
mediastinal node diagnosis (Fig. 1).
Diagnostic Efficacy of PET/CT (n = 184)
On a per-patient basis, the PET/CT had a diagnostic
efficacy for the detection of N2 disease of; sensitivity
(48%, 11/23), specificity (95%, 153/161), accuracy (89%,
164/184), and positive and negative predictive values
(68%, 11/19; 93%, 153/165, respectively).  
A total of 161 patients were classified in the P-TN group,
as opposed to 12 in the PET/CT FN group (Fig. 2) and 11
in the PET/CT TP (Fig. 3) group. The patient characteristics
FDG PET/CT for Mediastinal Nodal Detection and Prognostic Implications in T1 Lung Cancer
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AB
Fig. 3. True positive PET/CT interpreta-
tion for mediastinal nodal staging in 46-
year-old man with stage T1 adenocarci-
noma of lung showing metastatic
disease on follow-up examination.
A, B. Transverse images of initial
PET/CT show 29-mm-sized nodule
(arrow in A) with high amount of FDG
uptake (maximum SUV = 10.4) in right
lower lobe and right lower paratracheal
lymph node (nodal station 4R, arrow in
B) of high FDG uptake. Nodes
contained malignant cells upon
examination of mediastinoscopic biopsy. 
C, D. Initial (C) and follow-up (D)
enhanced sagittal T1-weighted MR
images over seven month follow-up
period show newly developed metastatic
nodule (arrow in D) in cerebellar vermis.
CDof the P-TN, PET/CT FN, and PET/CT TP groups were
based on the various clinicopathologic factors shown in
Table 1. 
Prognostic Implications
A total of 39 (21%) of the 184 patients in the study
experienced tumor recurrence. The recurrent sites were
the lungs in 13 patients, mediastinal lymph nodes in eight,
brain in six, lung and mediastinal nodes in four, bone in
four, and chest wall, trachea, adrenal gland, and liver in
one each. Table 2 shows the recurrence rates in terms of
patient characteristics by way of a univariate analysis of
the hazard ratios. Only the presence of mediastinal node
metastasis and high mSUVs were found to be significantly
Shin et al.
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Table 1. Characteristics of Patients in Pathologic True Negative, False Negative, and True Positive Groups
Based on Clinicopathologic Factors
P-TN FN TP P values
Age (years) 0.043
< 60 074 10 05
60 087 02 06
Sex 0.194
Female 054 05 01
Male 107 071 0
Smoking status 0.420
< 40 pack year index 044 09 07
40 pack year index 117 03 04
Extent of operation 0.201
Lobectomy/bilobectomy 160 12 10
Wedge/segmentectomy 001 00 01
Tumor size 0.159
20 mm in diameter 082 03 04
20 mm in diameter 079 09 07
Histology 0.333
Adenocarcinoma 114 10 08
Squamous cell carcinoma 038 01 01
Others 009 01 02
Note.─ P-TN = pathologic true negative cases including PET/CT true negative and PET/CT false positive cases, FN = PET/CT 
false negative cases, TP = PET/CT true positive cases.
Fig. 4. Diagram illustrating comparison of overall survival of 184
patients belonging to pathologic true negative (TN), PET/CT false
negative (FN), and true positive (TP) groups. Survival is signifi-
cantly better in true negative group than false negative or true
positive group. 
Fig. 5. Diagram illustrating comparison of disease-free survival of
184 patients belonging to pathologic true negative (TN), PET/CT
false negative (FN), and true positive (TP) groups. Disease-free
survival is significantly greater in true negative group than false
negative or true positive group.correlated with the presence of tumor recurrence. An
mSUV cutoff value of five proved to be the most discrimi-
native criteria of tumor recurrence, based on log-rank
probability values. The number of mediastinal nodal
stations involved with metastasis was not found to be a
predictor of tumor recurrence (four of seven patients
[57%], with a single nodal station metastasis experiencing
a recurrence and nine [56%] of 16 patients with multiple
nodal station metastases experiencing a recurrence;
yielding a hazard ratio of 1.402, p = 0.577). 
The factors achieving statistical significance by multivari-
ate analyses are summarized in Table 3. Both the presence
of mediastinal node metastases and an mSUV of > 5 were
found to be independent predictors of patient survival.
The three-year OS rate in the PET/CT FN group (43%,
95% confidence interval [CI]; 25.0 to 60.0%) was similar
to that of the TP group (49%, 95% CI; 29.9 to 67.5%) (p
= 0.863), however both groups had significantly lower OS
rates than the P-TN group (90%, 95% CI; 86.5 to 93.1) (p
< 0.001) (Fig. 4). Moreover, the three-year DFS rate in the
PET/CT FN group (31%, 95% CI; 13.6 to 48.0%) was not
statistically different from that of the TP group (16%, 95%
CI; 1.7 to 29.5%) (p = 0.649); however, both groups had
significantly lower DFS rates than the P-TN group (77%,
95% CI; 72.0 to 81.2%) (p < 0.001) (Fig. 5).
DISCUSSION
We found that the median OS in the PET/CT FN group
(29 months) was similar to the median OS time determined
for the TP group (28 months) (p = 0.863); however, both
groups had significantly shorter median OS times than the
P-TN group (41 months) (p < 0.001). In addition, the
median DFS in the PET/CT FN group (16 months) was
lower than the P-TN group (35 months) (p < 0.001);
however, no significant difference was found between the
FN and TP groups (12 months) (p = 0.649). Therefore,
patients diagnosed with pathologic mediastinal nodal
metastasis not detected by PET/CT had poorer survival
estimates than patients with pathologically negative nodes.
These findings suggest that a more sensitive and accurate
FDG PET/CT for Mediastinal Nodal Detection and Prognostic Implications in T1 Lung Cancer
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Table 2. Patient Characteristics and Univariate Analysis for Presence of Recurrent Disease
Number of Patients with Recurrent Disease Hazards Ratio (95% CI) P values
Node metastasis 2.656 (1.797 - 3.926) < 0.001
P-TN 26
FN 06
TP 07
Sex 1.322 (0.657 - 2.657) 0.434
Male 28
Female 11
Age (year) 1.325 (0.715 - 2.568) 0.388
< 60 17
60 22
Tumor size 1.193 (0.557 - 2.114) 0.585
> 20 mm 26
20 mm 13
mSUV 4.441 (1.734 - 11.372) 0.002
> 5 34
5 05
Histology 1.883 (0.580 - 2.758) 0.069
Squamous 07
Nonsquamous 32
Note.─ CI = confidence interval, P-TN = pathologic true negative, FN = PET/CT false negative cases, TP = PET/CT true positive 
casesm, MSUV = maximum standardized uptake value, Squamous = squamous cell carcinoma, Nonsquamous = lung cancer other
than squamous cell carcinoma
Table 3. Multivariate Cox Proportional Hazard Analysis of
Disease-Free Survival
Parameter Hazard Ratio 95% CI P values
Nodal metastasis 2.207 1.468 - 3.317  < 0.001
mSUV > 5 3.653 1.354 - 9.856 0.011
Tumor size 
(> 20 mm in diameter) 1.324 0.685 - 2.559 0.405
Note.─ CI = confidence interval, mSUV = maximum standardized uptake 
valuemeasure should be devised to correctly triage patients with
stage T1 NSCLC in terms of selecting a treatment modality
and predicting prognosis.
In our patient cohort, patient age, cell type, and primary
tumor size had no significant impact on OS. By both the
univariate and multivariate analyses, the presence of
pathologic N2 disease and a primary tumor with an mSUV
> 5.0 were found to be related to the recurrence of the
disease. 
Some disagreement exists concerning the relationship
between survival and the mSUVs of primary tumors (6-
17), which is probably attributable to the various identify-
ing methods used along with the related factors, such as,
disease stages (wide range of primary tumor sizes), tumor
staging accuracy, and the FDG uptake measures and
analytical methods used. In our study, which addressed
stage T1 lung cancers (< 30 mm in diameter) with an
mSUV of > 5.0, did appear to be significantly predict a
poor prognosis by using a multivariate Cox proportional
hazard analysis. 
It has been suggested that patients with a high SUV have
poorer DFS (6-10). Previous studies have shown that
different mSUV cut-off values ranging from 3.3 to 10 are
useful for predicting tumor recurrence (10-13). The differ-
ence in cutoff values between our results and those of
previous studies can be explained by differences in cancer
stages and NSCLC histology. It can be reasonably
presumed that patients with an advanced stage of lung
cancer have a higher SUV and poorer prognosis than those
with an early stage form of the disease. Moreover, it has
been reported that the relationship between FDG uptake
and tumor aggressiveness is significant in adenocarcinoma
cases, but not in other histologic types of NSCLC (14-16).
In contrast, Vesselle et al. (17) demonstrated that the FDG
uptake values of the primary NSCLCs do not provide
additional prognostic information beyond tumor size and
stage. Further, they reported that mSUV is positively
correlated with cancer stage and tumor size, but not
directly with patient prognosis. When measuring the
mSUVs of tumors < 28 mm in diameter (18, 19), the
effects of limited PET reconstructed resolution and artifi-
cially lowered tumor uptake value on the mSUVs should
be considered. Even after measuring partial-volume-
corrected tumor mSUVs, they still found no positive
relationship between mSUV and patient prognosis. In our
study, an mSUV of > 5.0 will help predict tumor
recurrence. However, cell types (adenocarcinoma versus
non-adenocarcinoma; squamous versus non-squamous
carcinomas) were not a significant prognosis determinant.
Primary tumor size is a recognized significant indepen-
dent prognostic factor in patients with NSCLC. Recently,
several studies have suggested that tumors < 2 cm have a
better prognosis than those of > 2 cm (20-23). In our
study, tumor size did not attain statistical significance by
multivariate analysis. Nevertheless, although no statistical
significance was not found, tumors of > 2 cm had more
mediastinal nodal metastases than those < 2 cm (p =
0.077). This lack of statistical significance, despite the
presence of a trend toward an effect for size > 2.0 cm, may
be due to the small number of our cohort and the small
number of node positive patients (12%, 23 of 184
patients). 
In our study, the PET/CT diagnostic efficacy for the
identification of N2 disease was based on sensitivity (48%,
11 of 23 patients), specificity (95%, 153 of 161), and
accuracy (89%, 164 of 184). The low sensitivity of
PET/CT for detecting N2 disease in patients with stage T1
lung cancer has already been reported (3, 4), and may be
explained by the fact that we only included patients with
early stages NSCLC (stage T1 cancer) and who had
undergone a curative surgical resection.
Our study suffers from several limitations. First, it may
include a selection bias. To aid the prognostic determina-
tion, we excluded patients who had not undergone surgical
treatment and those who had died of diseases not related
to lung cancer. This may have distorted the evaluation of
the efficacy of PET/CT in terms of its detection of mediasti-
nal nodal metastasis. Second, although we tried to perform
a comprehensive review of the clinical and tumor histol-
ogy-related factors related to prognosis, some potential
factors were omitted (e.g., performance status, tumor
lymphatic or vascular invasion by pathologic examination).
Finally, the follow-up period was relatively short
(maximum 44 months).
In conclusion, the PET/CT was found to have high a
specificity and negative predictive values, but low sensitiv-
ity for detecting N2 disease in patients with a stage T1
NSCLC. In addition, patients with PET/CT FN N2 disease
have survivals that are similar to those of PET/CT TP N2
disease patients, and which are both substantially shorter
than those of P-TN patients. Keeping in mind our study
results, we propose the following diagnostic and treatment
strategy for stage T1 NSCLCs: when PET/CT suggests the
presence of mediastinal nodal metastasis, mediastinoscopy
should be performed to confirm the presence of N2
disease. Next, treatment plan (positive results render
neoadjuvant chemoradiation therapy with or without
following surgery, whereas negative results render curative
resection with or without following adjuvant therapy)
should be determined according to the mediastinoscopy
results. When the PET/CT results suggest the absence of
mediastinal nodal metastasis, direct curative resection
Shin et al.
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therapy according to the pathologic results of the curative
surgery.
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